NASDAQ:GNVC - GenVec Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.19
+0.30 (1.20%)
Get New GenVec Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNVC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNVC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for GenVec in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.19.

N/A

The current consensus among 0 investment analysts is to n/a stock in GenVec. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2017HC WainwrightDowngradeHold$7.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
1/25/2017Rodman & RenshawDowngradeBuy ➝ Neutral$15.00 ➝ $7.00N/A
i
12/2/2016Rodman & RenshawBoost Price TargetBuy$2.30 ➝ $15.00N/A
i
Rating by Ram Selvaraju at Rodman & Renshaw
7/26/2016Roth CapitalReiterated RatingBuy$80.00 ➝ $20.00N/A
i
6/20/2016Rodman & RenshawReiterated RatingBuy$23.00N/A
i
(Data available from 6/14/2016 forward)
GenVec logo
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Read More

Today's Range

Now: $7.19
$7.19
$7.19

50 Day Range

MA: N/A

52 Week Range

Now: $7.19
$2.70
$10.44

Volume

N/A

Average Volume

259,136 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of GenVec?

The following sell-side analysts have issued stock ratings on GenVec in the last year:
View the latest analyst ratings for GNVC.

What is the current price target for GenVec?

0 Wall Street analysts have set twelve-month price targets for GenVec in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for GenVec in the next year.
View the latest price targets for GNVC.

What is the current consensus analyst rating for GenVec?

GenVec currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GNVC.

How do I contact GenVec's investor relations team?

GenVec's physical mailing address is 910 Clopper Rd Ste 220n, GAITHERSBURG, MD 20878-1353, United States. The biopharmaceutical company's listed phone number is +1-240-6320740. The official website for GenVec is www.genvec.com.